CRVS—(-6%/AH)—falls off the COVID-19 bandwagon: https://www.globenewswire.com/news-release/2021/07/15/2263919/0/en/Corvus-Pharmaceuticals-Discontinues-Phase-3-Study-of-Mupadolimab-Anti-CD73-for-COVID-19-Due-to-Vaccine-Effectiveness-in-Reducing-Hospitalizations.html